Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFederal University of Health Science of Porto Alegre

About this trial

Background: Infections of the central nervous system (CNS) are associated with high morbidity, mortality, and high resource consumption. The BioFire FilmArray is a molecular diagnostic panel capable of identifying 14 pathogens in approximately one hour, including bacteria, viruses, and fungi. However, it is not yet widely available in the Brazilian public health system.

Objective: The primary objective of this study is to evaluate the pre-test probability of positivity of the Biofire FilmArray bioMérieux Meningitis/Encephalitis panel in patients with clinical syndrome of meningitis and/or encephalitis and pleocytosis (CSF ≥ 5 cells).

As secondary objectives, the study aims to:

Determine the clinical impact of using the panel through variables such as total hospital stay and length of stay in the intensive care unit.

Compare the duration of antibiotic use in non-bacterial cases between groups. Compare the time to reduction of acyclovir use in etiologies without proven benefit.

Compare the time for identification of the causative pathogen and mortality rates between the study groups.

Perform a cost-effectiveness analysis of the test. Compare the request for imaging exams, such as brain MRI and CT scan, between the groups.

Methods: This is a prospective, transversal, and multicenter study conducted at Santa Casa de Porto Alegre and Hospital Dom João Becker. Patients will be compared with a retrospective cohort used as a control group.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Failure to sign the Informed Consent Form.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Biofire FilmArray Meningitis/Encephalitis Panel

    Diagnostic test

    The Biofire FilmArray is a multiplex molecular diagnostic test that will be performed on 0.2 mL of cerebrospinal fluid (CSF) collected from patients via lumbar or suboccipital puncture. The system automatically performs DNA/RNA extraction, purification, multiplex PCR, and identification of 14 different pathogens (6 bacteria, 7 viruses, and 1 fungus). The complete process takes approximately one hour and provides qualitative results to guide therapeutic decisions such as antibiotic stewardship.

Treatment groups

182 Participants
are divided into 2 treatment groups
Group A: Biofire FilmArray groupExperimental treatment 1 intervention
Group B: Retrospective Control GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Rate of BioFire® FilmArray® Meningitis/Encephalitis Panel Positivity

Proportion of positive BioFire® FilmArray® Meningitis/Encephalitis panel results among participants presenting with a clinical syndrome of meningitis and/or encephalitis and cerebrospinal fluid pleocytosis (≥ 5 cells/mm³).

Time frame
At the time of BioFire® FilmArray® result availability, assessed up to 24 months

Secondary outcomes

1

Total hospital length of stay in days

Duration of hospitalization, measured in days, compared between study groups.

Time frame
From hospital admission until hospital discharge or death, whichever occurs first, assessed up to 24 months.
2

Intensive care unit length of stay in days

Duration of intensive care unit stay, measured in days, compared between study groups.

Time frame
From intensive care unit admission until intensive care unit discharge or death, whichever occurs first, assessed up to 24 months.
3

Duration of antibiotic therapy in participants without confirmed bacterial infection

Duration of systemic antibiotic therapy, measured in days, compared between study groups in participants without confirmed bacterial etiology.

Time frame
From antibiotic initiation until discontinuation, hospital discharge, or death, whichever occurs first, assessed up to 24 months.
4

Duration of acyclovir therapy in participants without confirmed indication

Duration of acyclovir therapy, measured in days, compared between study groups in participants without confirmed indication of benefit.

Time frame
From acyclovir initiation until discontinuation, hospital discharge, or death, whichever occurs first, assessed up to 24 months.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Federal University of Health Science of Porto Alegre

Lead sponsor

Irmandade Santa Casa de Misericórdia de Porto Alegre

Collaborator

BioMérieux

Collaborator